Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV
Laurus Labs has reported total income of Rs. 1,458.20 crores during the period ended March 31, 2024
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
Sales reflect continued strong growth in oncology and vaccines
Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024
The company will closely work with the USFDA to address and respond to the observations in an expeditious manner
One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
Subscribe To Our Newsletter & Stay Updated
